home / stock / inmb / inmb quote
Last: | $ |
---|---|
Change Percent: | 3.27% |
Open: | $5.00 |
Close: | $5.05 |
High: | $5.30 |
Low: | $4.8001 |
Volume: | 22,030 |
Last Trade Date Time: | 02/12/2020 04:40:27 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $5.00 | $5.05 | $5.30 | $4.8001 | 22,030 | 02-12-2020 |
$ | $5.15 | $4.89 | $5.20 | $4.89 | 12,979 | 02-11-2020 |
$ | $4.96 | $5.075 | $5.25 | $4.85 | 35,299 | 02-10-2020 |
$ | $5.05 | $4.9851 | $5.09 | $4.876 | 17,276 | 02-07-2020 |
$ | $5.39 | $5.0272 | $5.40 | $4.90 | 17,544 | 02-06-2020 |
$ | $4.90 | $4.90 | $5.1031 | $4.90 | 7,740 | 02-05-2020 |
$ | $4.8441 | $4.7811 | $4.9123 | $4.70 | 15,667 | 02-04-2020 |
$ | $4.94 | $4.75 | $4.9531 | $4.75 | 12,019 | 02-03-2020 |
$ | $4.8614 | $4.93 | $5.00 | $4.85 | 4,282 | 01-31-2020 |
$ | $4.80 | $4.78 | $4.80 | $4.77 | 5,549 | 01-30-2020 |
$ | $5.2746 | $4.9198 | $5.2746 | $4.9198 | 8,917 | 01-29-2020 |
$ | $4.9785 | $5.1354 | $5.1354 | $4.9224 | 4,522 | 01-28-2020 |
$ | $5.03 | $4.82 | $5.0539 | $4.70 | 6,074 | 01-27-2020 |
$ | $5.24 | $4.995 | $5.24 | $4.98 | 19,577 | 01-24-2020 |
$ | $5.29 | $4.95 | $5.32 | $4.75 | 34,088 | 01-23-2020 |
$ | $5.6777 | $5.2502 | $5.6777 | $5.25 | 20,294 | 01-22-2020 |
$ | $5.58 | $5.60 | $5.6216 | $5.52 | 11,951 | 01-21-2020 |
$ | $5.68 | $5.66 | $5.7134 | $5.65 | 10,117 | 01-20-2020 |
$ | $5.68 | $5.66 | $5.7134 | $5.65 | 10,117 | 01-17-2020 |
$ | $5.6101 | $5.68 | $5.8382 | $5.57 | 13,358 | 01-16-2020 |
News, Short Squeeze, Breakout and More Instantly...
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 25, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a...
Publication of detailed analysis on INKmune biology compared to cytokine stimulated cells demonstrates important anti-tumor memory like NK cell characteristics BOCA RATON, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinic...
The planned interim analysis confirms the accuracy of the sample size calculations and statistical power for EMACC, the primary endpoint. The interim analysis, performed by a third-party, demonstrated no need to change trial design or size. BOCA RATON, Fla., June 27, 2024 (GLOBE N...